Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

INDIGO

Financiado

Cerrado

Investigation of Novel biomarkers and Definition of the role of the microbiome...

Investigation of Novel biomarkers and Definition of the role of the microbiome In Graves Orbitopathy INDIGO . Graves' orbitopathy (GO), also known as thyroid eye disease, affects approximately 3 million people in Europe with an estimated socioeconomic burden of 6.4 billion euros per annum. GO is a complication of Graves' disease which is... ver más

30/04/2018

CARDIFF UNIVERSITY

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

CARDIFF UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2018-04-30 No tenemos la información de la convocatoria

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

CARDIFF UNIVERSITY

0.00€ | Lider

UKESSEN

N.D. | Participante

PTP

N.D. | Participante

UMIL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

CARDIFF UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Graves' orbitopathy (GO), also known as thyroid eye disease, affects approximately 3 million people in Europe with an estimated socioeconomic burden of 6.4 billion euros per annum. GO is a complication of Graves' disease which is an autoimmune disease and the commonest cause of an overactive thyroid gland. The treatment of GO remains unsatisfactory and the majority of patients report long-term impairment of quality of life. To improve the outcomes of people with GO and thus reduce long-term illness and cost to society, research is needed to address the identification of risk factors, develop a better understanding of the pathophysiology of the disease, devise approaches for early diagnosis during the pre-clinical stage of the disease, and create novel and safe interventions. INDIGO will refine and optimise animal and in vitro models of Graves’ disease and GO, which are urgently required to facilitate the study of the pathogenesis of GO. INDIGO will address the identification of risk factors for the initiation and perpetuation of autoimmunity that causes disease, using the latest generation technologies to study variations in the microbiome in Graves and GO patients and controls. The interaction of the gut derived antigens, from micro-organisms and nutrients on the autoimmune response in both the animal model by probiotic and contra-biotic intervention. State of the art technology will be used to search for biomarkers that will identify patients that will progress to GO, during the preclinical phase of the disease when intervention is most likely to be successful. The successful completion of the project will be ensured by a partnership involving 2 SMEs, 3 academic institutions and the European Group on Graves' Orbitopathy, each contributing complementary expertise and technology, the project will involve 5 secondments and 3 recruitments that will facilitate the exchange of knowledge and training.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores